Source: Coskun et al., The Lancet 2022 Phase 2 Results Phase 2 -- Obesity (NEJM 2023) NCT04881760 | Published: New England Journal of Medicine , 2023 (Jastreboff AM, et al.) This was the landmark Phase 2 trial that put retatrutide on the map
Every batch is rigorously tested to confirm its purity and identity
In addition, all currently available GLP-1R therapies are peptide agonists, most of which require subcutaneous administration [140]
For dosing protocols and titration schedules, see the retatrutide dosing guide
Delivery methods other than injections and oral pills, such as sublingual drops and dissolving tablets, have not been tested in clinical trials
Our GLP-1 Medications are available at all Elevated Health Clinics.